(Total Views: 297)
Posted On: 07/01/2019 5:05:09 AM
Post# of 154999
Here's an example of buying a company like CYDY from 2016., something that would be comparable to the action of Leronlimab on Cancers.After good internal results for mTNBC, such transactions would be possible. That would be $ 10 immediately and $ 5 after, per share.
Probably below that price NP and RP would not accept the offer.
"Transaction Terms
AbbVie will acquire Stemcentrx for approximately $5.8 billion in cash and stock. AbbVie will pay approximately $2.0 billion of the transaction value in cash and fund the remaining portion with stock. In addition, Stemcentrx investors are eligible to receive up to $4 billion in cash for additional, success-based milestone payments for the achievement of certain regulatory and clinical developments."
https://news.abbvie.com/news/abbvie-to-expand...cancer.htm
Probably below that price NP and RP would not accept the offer.
"Transaction Terms
AbbVie will acquire Stemcentrx for approximately $5.8 billion in cash and stock. AbbVie will pay approximately $2.0 billion of the transaction value in cash and fund the remaining portion with stock. In addition, Stemcentrx investors are eligible to receive up to $4 billion in cash for additional, success-based milestone payments for the achievement of certain regulatory and clinical developments."
https://news.abbvie.com/news/abbvie-to-expand...cancer.htm
(1)
(0)
